Stocks · News reference
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
One drop works to significantly reduce redness, with results lasting up to 12 hours1Lasts up to 50% longer than Lumify1-2,*Expands Alcon's portfolio of consumer eye care solutions and will be available in major
BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and lowers the price target from $82 to $74.
Barclays analyst Christopher Pasquale initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of $70.
- Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1- 100% of participants who received encaleret reported improvements in at least one ADH1
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically
Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $157 to $156.